Chemotherapy for metastatic castration-sensitive prostate cancer

被引：13
作者：
Parimi, Sunil [1 ]
Chi, Kim N. [1 ,2 ]
机构：
[1] British Columbia Canc Agcy, 600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada
[2] Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2016年 / 23卷 / 09期
关键词：
castration sensitive; chemotherapy; docetaxel; metastatic; prostate cancer; ANDROGEN-DEPRIVATION THERAPY; CHEMOHORMONAL THERAPY; ZOLEDRONIC ACID; PHASE-III; RADIATION-THERAPY; CONTROLLED-TRIAL; DOCETAXEL; ESTRAMUSTINE; MEN; PREDNISONE;
D O I：
10.1111/iju.13148
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Incorporation of docetaxel into metastatic castration-sensitive prostate cancer treatment has added a new treatment option to a disease state that had previously not seen change for decades. Early attempts of a chemo-hormonal approach for castration-sensitive prostate cancer were not successful. With the demonstration of survival benefits using docetaxel in patients with metastatic castration-resistant prostate cancer, this encouraged continued research with docetaxel given earlier in the disease course. Three randomized phase III trials have defined the benefits of docetaxel in the metastatic castration-sensitive prostate cancer setting; however, there remain questions and controversies on the appropriate and optimal patient selection.
引用
收藏
页码：726 / 733
页数：8
相关论文
共 52 条
  • [1] Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
    Attard, Gerhardt
    Cooper, Colin S.
    de Bono, Johann S.
    [J]. CANCER CELL, 2009, 16 (06) : 458 - 462
  • [2] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [3] Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
    Darshan, Medha S.
    Loftus, Matthew S.
    Thadani-Mulero, Maria
    Levy, Benjamin P.
    Escuin, Daniel
    Zhou, Xi Kathy
    Gjyrezi, Ada
    Chanel-Vos, Chantal
    Shen, Ruoqian
    Tagawa, Scott T.
    Bander, Neil H.
    Nanus, David M.
    Giannakakou, Paraskevi
    [J]. CANCER RESEARCH, 2011, 71 (18) : 6019 - 6029
  • [4] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
  • [5] Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer
    Dorff, T. B.
    Crawford, E. D.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 31 - 38
  • [6] Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer
    Eigl, BJC
    Eggener, SE
    Baybik, J
    Ettinger, S
    Chi, KN
    Nelson, C
    Wang, Z
    Gleave, ME
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4905 - 4911
  • [7] European Association of Eurology, 2016, PROSTATE CANC
  • [8] Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
    Fizazi, Karim
    Faivre, Laura
    Lesaunier, Francois
    Delva, Remy
    Gravis, Gwenaelle
    Rolland, Frederic
    Priou, Frank
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Cnristine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Flechon, Aude
    Ravaud, Alain
    Cojean-Zelek, Isabelle
    Oudard, Stephane
    Labourey, Jean-Luc
    Chinet-Charrot, Paule
    Legouffe, Eric
    Lagrange, Jean-Leon
    Linassier, Claude
    Deplanque, Gael
    Beuzeboc, Philippe
    Davin, Jean-Louis
    Martin, Anne-Laure
    Habibian, Muriel
    Laplanche, Agnes
    Culine, Stephane
    [J]. LANCET ONCOLOGY, 2015, 16 (07) : 787 - 794
  • [9] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Fizazi, Karim
    Carducci, Michael
    Smith, Matthew
    Damiao, Ronaldo
    Brown, Janet
    Karsh, Lawrence
    Milecki, Piotr
    Shore, Neal
    Rader, Michael
    Wang, Huei
    Jiang, Qi
    Tadros, Sylvia
    Dansey, Roger
    Goessl, Carsten
    [J]. LANCET, 2011, 377 (9768) : 813 - 822
  • [10] Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning
    Glass, TR
    Tangen, CM
    Crawford, ED
    Thompson, I
    [J]. JOURNAL OF UROLOGY, 2003, 169 (01) : 164 - 169
123456